Business
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
Vivo Empowers Clinical Development Teams to Accelerate Decision-making and Analyses in Clinical Trials for Improved Outcomes HOUSTON and BOCA RATON, Fla.,
About this update from Inmune Bio Inc.
[{"type":"text","content":"Vivo Empowers Clinical Development Teams to Accelerate Decision-making and Analyses in Clinical Trials for Improved Outcomes HOUSTON and BOCA RATON, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- OmniScience and INmune Bio (NASDAQ: INMB) today announced a pioneering partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer’s disease (AD) clinical trial (the “AD02 trial”) using OmniScience’s flagship product, Vivo, an industry-first, genAI-powered control tower designed specifically for centralizing and analyzing vast clinical data in real time. This solution represents a innovative approach to clinical research, delivering immediate insights that enhance decision-making and transform traditional, time-consuming trial management. Vivo securely unifies data across sources including electronic data capture (EDC), clinical trial management systems (CTMS), patient-reported outcomes (PROs)/clinical outcome assessments (COAs), labs, sensors/wearables, safety databases, and more. With fully integrated data, Vivo goes beyond dashboard visualizations to enable clinical trial teams to improve their decision-making, accelerate timelines, enhance patient safety, and ultimately improve health outcomes. Designed with explainability and interpretability at its core, Vivo ensures that every generated insight is supported by clear, traceable rationale grounded in data and clinical context. Its advanced cognitive architecture combines ontological knowledge of trial protocols with domain-specific clinical expertise, enabling qualitative and quantitative reasoning at scale. INmune Bio recently announced it completed randomization of patients for its blinded AD02 trial for patients with early AD and biomarkers of elevated neuroinflammation. The trial overenrolled with a total of 208 patients, 56% of whom were categorized as mild AD and 44% as mild cognitive impairment. INmune Bio plans to release top-line cognitive results in the second quarter of 2025. “A global trial of this size is vast, and Vivo will be critical in our ability to analyze cognitive results,” stated Tara Lehner, INmune Bio’s VP of Clinical Operations. “With genAI provided by Vivo, we can amplify our clinical teams’ capabilities, turning complex data into actionable insights at unprecedented speed, which means we can get answers—and treatments—to patients faster.” I...